Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A breakthrough for chronic hive sufferers. The FDA has approved remibrutinib (Rhapsido) as the first treatment specifically for symptomatic dermographism (SD) in adults whose condition isn't controlled by antihistamines. The oral BTK inhibitor showed twice the complete response rate versus placebo in the phase 3 RemIND trial, with some patients seeing relief as early as week 2.
A breakthrough for chronic hive sufferers. The FDA has approved remibrutinib (Rhapsido) as the first-ever treatment specifically indicated for symptomatic dermographism (SD) in adults inadequately controlled by H1 antihistamines. SD — triggered by everyday skin friction, scratching, or clothing pressure — affects more than 90% of people with chronic hives, yet more than half remain symptomatic despite antihistamine therapy. Until now, clinicians had no approved, disease-specific option for this population.
Remibrutinib is an oral, highly selective Bruton's tyrosine kinase inhibitor (BTKi) that blocks histamine-release pathways. It was previously approved for chronic spontaneous urticaria (CSU) in September 2025. The new SD indication was supported by the phase 3 RemIND trial, which showed significantly higher complete response rates with remibrutinib versus placebo, with some patients responding as early as week 2.
By the Numbers:
Why it matters: This approval validates BTK inhibition as a strategy across immune-mediated skin diseases and gives clinicians a first evidence-based, FDA-approved tool for SD. Experts caution, however, that insurance coverage — not just FDA approval — will be the real-world hurdle for patient access, making thorough documentation of diagnosis, disease burden, and prior treatment history essential.
